Viewing Study NCT00498225



Ignite Creation Date: 2024-05-05 @ 6:31 PM
Last Modification Date: 2024-10-26 @ 9:34 AM
Study NCT ID: NCT00498225
Status: COMPLETED
Last Update Posted: 2012-11-02
First Post: 2007-07-06

Brief Title: Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
Sponsor: Taiho Pharmaceutical Co Ltd
Organization: Taiho Pharmaceutical Co Ltd

Study Overview

Official Title: Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer With Local Progression or Metastasis
Status: COMPLETED
Status Verified Date: 2012-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GEST
Brief Summary: In patients with unresectable advanced pancreatic cancer non-inferiority of TS-1 monotherapy and superiority of GEM TS-1 combination therapy to gemcitabine GEM will be verified using survival time
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None